Chemistry:Etirinotecan pegol

From HandWiki
Revision as of 15:44, 26 June 2023 by ScienceGen (talk | contribs) (add)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Short description: Pharmaceutical drug
Etirinotecan pegol
Etirinotecan pegol.svg
Clinical data
Trade namesOnzeald
Other namesNKTR-102
Routes of
administration
Intravenous infusion
ATC code
Pharmacokinetic data
Protein bindingnone
Metabolitesirinotecan and its metabolites
Elimination half-life38 days
Excretionmostly via kidneys
Identifiers
CAS Number
DrugBank
UNII
KEGG
Chemical and physical data
FormulaC153H176N20O36[C8H16O4]n (n≈113)
Molar mass20,900–24,900 g/mol[1]

Etirinotecan pegol (trade name Onzeald) is a drug developed by Nektar Therapeutics for the treatment of certain kinds of breast cancer with brain metastases. The European Medicines Agency refused to grant it a marketing authorisation in 2017.[2]

It works as a topoisomerase I inhibitor.[3] Chemically, it consists of four units of irinotecan (a topoisomerase I inhibitor in use since the late 1990s[4]) linked by carboxymethyl glycine and polyethylene glycol (PEG) chains to a central pentaerythritol ether, resulting in a much longer biological half-life (38 days) than that of irinotecan. It is formulated as a dihydrochloride and with 1.2 units of trifluoroacetate.[1]

References

  1. 1.0 1.1 "Onzeald: EPAR – Refusal public assessment report". European Medicines Agency. 2018-02-02. https://www.ema.europa.eu/documents/assessment-report/onzeald-epar-refusal-public-assessment-report_en.pdf. 
  2. "Onzeald". European Medicines Agency. 2017-11-10. https://www.ema.europa.eu/en/medicines/human/EPAR/onzeald. 
  3. "Health-related quality of life in patients with locally recurrent or metastatic breast cancer treated with etirinotecan pegol versus treatment of physician's choice: Results from the randomised phase III BEACON trial". European Journal of Cancer 76: 205–215. May 2017. doi:10.1016/j.ejca.2017.02.011. PMID 28360015. 
  4. "Drug Approval Package: Camptosar (Irinotecan Hydrochloride) NDA# 20-571/S-008". https://www.accessdata.fda.gov/drugsatfda_docs/nda/98/020571s008.cfm.